NLS Pharmaceutics (NCEL) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics Ltd. (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly conditions involving excessive daytime sleepiness and impaired wakefulness.

The company’s lead development program is Quilience, an extended-release formulation of mazindol being investigated for sleep-wake disorders, including narcolepsy and idiopathic hypersomnia. NLS Pharmaceutics has also pursued additional mazindol-based therapies and other potential treatments for neurological and psychiatric conditions.

NLS Pharmaceutics is headquartered in Switzerland and conducts its research and clinical development activities through collaborations and programs intended for international markets. As a development-stage company, its product candidates remain subject to clinical testing and regulatory review before they can be commercialized.

Key Stats

• Today's Range: $2.98 to $3.04
• 50-Day Range: $2.85 to $3.60
• 52-Week Range: $1.83 to $19.07
• Volume: 1,463 shs
• Average Volume: 51,007 shs
• Market Capitalization: $17.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Hold

NLS Pharmaceutics Stock Analysis - MarketRank™

NLS Pharmaceutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 651st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

NLS Pharmaceutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

NLS Pharmaceutics has a consensus price target of $23.00, representing about 656.6% upside from its current price of $3.04.

Amount of Analyst Coverage

NLS Pharmaceutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

NLS Pharmaceutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of NLS Pharmaceutics has been sold short.

Short Interest Ratio / Days to Cover

NLS Pharmaceutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NLS Pharmaceutics has recently decreased by 23.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NLS Pharmaceutics does not currently pay a dividend.

Dividend Growth

NLS Pharmaceutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NLS Pharmaceutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

NLS Pharmaceutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/18/2026
• Today: 10/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NCEL
• Previous Symbol: NASDAQ:NLSP
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NLS Pharmaceutics: $23.00
• High Price Target: $23.00
• Low Price Target: $23.00
• Potential Upside/Downside: +656.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.59 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 5,780,000
• Free Float: 4,829,000
• Market Cap: $17.57 million
• Optionable: Not Optionable
• Beta: 0.99